10.28
-0.35 (-3.29%)
| Penutupan Terdahulu | 10.63 |
| Jumlah Dagangan | 20,291 |
| Harga / Buku (P/B) | 3.21 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -0.990 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.94% |
| Nisbah Semasa (MRQ) | 28.37 |
| Aliran Tunai Operasi (OCF TTM) | -47.45 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -28.64 M |
| Pulangan Atas Aset (ROA TTM) | -16.56% |
| Pulangan Atas Ekuiti (ROE TTM) | -22.59% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Design Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.6 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | 0.0 |
| Persekitaran Makro | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | -0.44 |
|
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 36.09% |
| % Dimiliki oleh Institusi | 61.09% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Logos Global Management Lp | 30 Jun 2026 | 3,000,000 |
| Frazier Life Sciences Management, L.P. | 30 Jun 2026 | 1,809,854 |
| Caption Management, Llc | 30 Jun 2026 | 1,118,098 |
| Sofinnova Investments, Inc. | 30 Jun 2026 | 865,135 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |